Clinical Trial Detail

NCT ID NCT04023071
Title FT516 in Subjects With Advanced Hematologic Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Fate Therapeutics
Indications

B-cell lymphoma

acute myeloid leukemia

Therapies

Aldesleukin + Cyclophosphamide + Fludarabine + FT516 + Obinutuzumab

Aldesleukin + Cyclophosphamide + Fludarabine + FT516 + Rituximab

Aldesleukin + Cyclophosphamide + Fludarabine + FT516

Age Groups: adult senior

No variant requirements are available.